ADAM metalloprotease-disintegrins share a common modular structure of functional domains for proteolytic, cell adhesion, and signaling interactions. The metalloprotease domain of oughly half of the known ADAMs contain an intact consensus metzincin catalytic site, and they are thus thought to function as active metalloproteases. The types of interactions mediated by ADAMs are expressly conspicu...

Experiments were performed to determine the effect of community composition on system function (bacterial production) in arctic Alaska. In this system bacterial production is controlled by: community, temperature, nutrients, and carbon source. Lake inlet and outlet communities in these experiments were different in composition, based on PCR-DGGE fingerprinting of 16S rDNA. For both communities,...

Predictor-corrector (PC) methods for the numerical solution of stiff ODEs can be extended to include the second derivative of the solution. In this paper, we consider second derivative PC methods with the three-step second derivative Adams-Bashforth as predictor and two-step second derivative Adams-Moulton as corrector which both methods have order six. Implementation of the proposed PC method ...

Adams, D. H. (1950). Brit. J. Cancer, 4, 183. Adams, D. H. (1951 a). Brit. J. Cancer, 5, 115. Adams, D. H. (1951 b). Brit. J. Cancer, 5, 409. Adams, D. H. (1952). Biochem. J. 50, 486. Adams, D. H. (1953). Biochem. J. 54; 328. Adams, D. H. (1955). Biochem. J. 60, 568. Buchanan, J. M., Hastings, A. B. & Nesbett, F. N. (1949). J. biol. Chem. 180, 435. Greenfield, R. E. & Meister, A. (1951). J. nat...

in this study, dynamic behavior of a controller's self destruction mechanism has been simulated using 3d-fem in adams software and investigated. this paper has been concentrated on high acceleration controller's projectiles. this controller is mechanical and has been placed in top of the projectile. the goal of this study is to investigate the destruction mechanism operation i.e. movement of pi...

Merck & Co., Inc. (Whitehouse Station, NJ), announced that it has successfully completed its $430 million acquisition of Inspire Pharmaceuticals, Inc. (Raleigh, NC). The cash tender offer for all outstanding shares (75.4%) of common stock of Inspire was completed by Monarch Transaction Corp., a wholly owned subsidiary of Merck. The deal, announced in February 2011, allows Merck to expand its op...